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Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most economically important
health challenges that currently exists in the global swine industry. PRRSV is an enveloped, single-stranded,
positive-sense RNA virus belonging to genus Arterivirus. A PRRSV infection is clinically characterized by
reproductive failure in sows and/or respiratory disease in growing pigs, causing significant economic losses
(Zimmerman et al., 2012). RNA viruses have relatively high mutation rates compared to DNA viruses, mainly
due to the low fidelity of viral RNA-dependent RNA polymerases (Arnold et al., 2005; Vignuzzi et al., 2008).
This rapid high mutation rate usually leads to the generation of genetically and antigenically variable virus
strains in the field, which can hinder the development of effective vaccines. PRRSV is currently classified into
two distinct genotypes, type 1 and type 2 which differs significantly in term of their clinical, and genetic
properties (Kapur et al., 1996; Labarque et al., 2004; Nelson et al., 1993). Within type 2, it has been proposed
a further subdivision into 9 genetic lineages (Shi et al., 2010). The extensive heterogeneity of PRRSV presents
challenges for the efficacy vaccines, which are currently based on a single virus strain. Consequently, the
current commercially vaccines confer partial cross-protection against heterologous PRRSV strains (Kimman
et al., 2009; Li et al., 2014; Murtaugh and Genzow, 2011), which is sufficient to significantly decrease duration
and magnitude of viremia, shedding, and lung lesions. In previous cross-protection studies, type 2 PRRSV
modified live vaccine have not been effective when applied to control pigs against type 1 PRRSV (Labarque et
al., 2003; van Woensel et al., 1998; Labarque et al., 2000). Cross-protection discoursed by type 2 PRRSV
vaccine against type 1 PRRSV is an important clinical issue in many Asian countries because of the emergence
of type 1 PRRSV (Chen et al., 2011; Nam et al., 2009; Thanawongnuwech et al., 2004). A modified live type 2
PRRSV vaccine (Fostera PRRS, Zoetis, Parsippany, NJ, USA) was introduced in the US in 2012, and is
profess to be efficacious to protect pigs against heterologous type 2 PRRSV challenge (Park et al., 2014), and
has been licensed to produce better cross-protection against heterologous PRRSV challenge. Fostera PRRS is
an attenuated PRRSV vaccine, passaged first on pig kidney cells engineered to constitutively express the
porcine CD163 PRRS receptor, then on baby hamster kidney cells that were also engineered to express
porcine CD163. The commercial modified live PRRS vaccines were attenuated by passage on African green
monkey kidney cells (cell line MA-104 and derivatives), which inappropriately express the macrophage-
specific CD163 PRRS receptor. Adaptation of the virus to use the monkey CD163 receptor contributes to the
observed attenuation phenotype of at least some of these vaccines, namely a reduced ability of the vaccine
virus to infect the host target cell, primary porcine alveolar macrophages (Pearce et al., 2014). In contrast, the
Fostera PRRSv is passaged only on cells expressing porcine CD163, and thus potentially maintaining its
ability to replicate to high titer on primary porcine alveolar macrophages. This fundamental difference in
attenuation may play a role in the dynamics of viremia in pigs, following challenge with PRRS viruses from
genotypes 1 (Charoenchanikran et al., 2016; Choi et al., 2016; Do et al., 2015; Park et al., 2015, 2014; Savard
et al., 2016; Tian et al., 2015).
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Introduction 24 
Rationale 25 
Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most economically 26 
important health challenges that currently exists in the global swine industry. PRRSV is an 27 
enveloped, single-stranded, positive-sense RNA virus belonging to genus Arterivirus. A PRRSV 28 
infection is clinically characterized by reproductive failure in sows and/or respiratory disease in 29 
growing pigs, causing significant economic losses (Zimmerman et al., 2012). RNA viruses have 30 
relatively high mutation rates compared to DNA viruses, mainly due to the low fidelity of viral 31 
RNA-dependent RNA polymerases (Arnold et al., 2005; Vignuzzi et al., 2008). This rapid high 32 
mutation rate usually leads to the generation of genetically and antigenically variable virus 33 
strains in the field, which can hinder the development of effective vaccines. PRRSV is currently 34 
classified into two distinct genotypes, type 1 and type 2 which differs significantly in term of 35 
their clinical, and genetic properties (Kapur et al., 1996; Labarque et al., 2004; Nelson et al., 36 
1993). Within type 2, it has been proposed a further subdivision into 9 genetic lineages (Shi et 37 
al., 2010). The extensive heterogeneity of PRRSV presents challenges for the efficacy vaccines, 38 
which are currently based on a single virus strain. Consequently, the current commercially 39 
vaccines confer partial cross-protection against heterologous PRRSV strains (Kimman et al., 40 
2009; Li et al., 2014; Murtaugh and Genzow, 2011), which is sufficient to significantly decrease 41 
 duration and magnitude of viremia, shedding, and lung lesions. In previous cross-protection 42 
studies, type 2 PRRSV modified live vaccine have not been effective when applied to control 43 
pigs against type 1 PRRSV (Labarque et al., 2003; van Woensel et al., 1998; Labarque et al., 44 
2000). Cross-protection discoursed by type 2 PRRSV vaccine against type 1 PRRSV is an 45 
important clinical issue in many Asian countries because of the emergence of type 1 PRRSV 46 
(Chen et al., 2011; Nam et al., 2009; Thanawongnuwech et al., 2004). A modified live type 2 47 
PRRSV vaccine (Fostera PRRS, Zoetis, Parsippany, NJ, USA) was introduced in the US in 2012, 48 
and is profess to be efficacious to protect pigs against heterologous type 2 PRRSV challenge 49 
(Park et al., 2014), and has been licensed to produce better cross-protection against heterologous 50 
PRRSV challenge. Fostera PRRS is an attenuated PRRSV vaccine, passaged first on pig kidney 51 
cells engineered to constitutively express the porcine CD163 PRRS receptor, then on baby 52 
hamster kidney cells that were also engineered to express porcine CD163. The commercial 53 
modified live PRRS vaccines were attenuated by passage on African green monkey kidney cells 54 
(cell line MA-104 and derivatives), which inappropriately express the macrophage-specific 55 
CD163 PRRS receptor. Adaptation of the virus to use the monkey CD163 receptor contributes to 56 
the observed attenuation phenotype of at least some of these vaccines, namely a reduced ability 57 
of the vaccine virus to infect the host target cell, primary porcine alveolar macrophages (Pearce 58 
et al., 2014). In contrast, the Fostera PRRSv is passaged only on cells expressing porcine CD163, 59 
and thus potentially maintaining its ability to replicate to high titer on primary porcine alveolar 60 
macrophages. This fundamental difference in attenuation may play a role in the dynamics of 61 
viremia in pigs, following challenge with PRRS viruses from genotypes 1 (Charoenchanikran et 62 
al., 2016; Choi et al., 2016; Do et al., 2015; Park et al., 2015, 2014; Savard et al., 2016; Tian et 63 
al., 2015).  64 
 Objectives 65 
The objective of this study was to summarize the efficacy of a type 2 modified live PRRSV 66 
vaccine (Fostera PRRS, Zoetis, Parsippany, NJ, USA) against heterologous PRRSV challenge in 67 
growing pigs. The primary outcome of interest was magnitude of macroscopic lung lesions, and 68 
the secondary outcome variables included viremia levels and average daily gain.  69 
For the purpose of this study, efficacy was described using the mean macroscopic lung score, 70 
representing an estimate of the percentage of lung affected by pneumonia. Each lung lobe was 71 
assigned a number to reflect the approximate volume percentage of the entire lung represented 72 
by that lobe. 73 
Methods 74 
Eligibility criteria:  75 
Population 76 
The population of the interest was peer reviewed manuscripts, and proceeding papers about 77 
clinical trials on the efficacy of Fostera PRRSV vaccine (Zoetis, Parsippany, NJ, USA). Age of 78 
the enrolled pigs, or country where trials were carried out will not be used as an exclusion factor.  79 
Intervention 80 
Eligible intervention is Fostera modified live PRRSV type 2 vaccine.  81 
Comparator 82 
Unvaccinated challenged pigs. 83 
Outcome 84 
 The primary outcome of interest is macroscopic lung lesion mean score, and the secondary 85 
outcome of interest are level of viremia (log10 TCID50/mL), duration of viremia and average 86 
daily gain (ADG) at different days’ post challenge with wild type heterologous PRRSV. 87 
Studies:  88 
Eligible studies will be randomized controlled parallel trials that allocate individual level study 89 
population of swine. At least one treatment arm i.e. challenged and vaccinated with Fostera 90 
PRRSV vaccine (Zoetis, Parsippany, NJ, USA), and a concurrent comparison arm i.e. challenged 91 
and unvaccinated. They should have at least one of the three outcomes reported. 92 
Information sources: 93 
MEDLINE and the Centre for Biosciences and Agriculture International (CABI) databases will 94 
be searched using the Iowa State University (ISU) Web of Science interface. The search strategy 95 
will be restricted from January 2012 to March 2018 because this type 2 PRRSV vaccine (Fostera 96 
PRRS, Zoetis, Florham Park, NJ, USA) was not available before 2012. Reference lists of 97 
relevant manuscripts and the table of contents from the last 6 years of the proceedings of the 98 
American Association of Swine Veterinarians (AASV), James McKean Iowa State University 99 
Swine Disease Conference, Allen D. Leman Swine Conference, North American PRRS 100 
symposium, and International Pig Veterinary Society Congress (IPVS) will be also searched for 101 
eligible studies.  The search will involve searching for the term “Fostera” only for the Swine 102 
Information Library (SIL) excluding Journal of Swine Health & Production (JSHAP) text and 103 
abstracts, web pages, and AASV news. For this resource the title will be screened, and if it 104 
appears relevant, the paper will be evaluated. Recent review manuscripts of Fostera MLV 105 
PRRSV will be examined for additional reports potentially missed by our database search. The 106 
bibliography of relevant manuscripts will also be assessed for relevant manuscripts.  107 
 Search strategy: 108 
An example search strategy is listed in Table 1. The search will not be restricted by language but 109 
we will be restricted by years (2012-2018).  110 
Search Number Search string  No of Results 
1 TS= (pig OR porcine OR 
swine OR hog) 
185,099 
2 TS= (Fostera OR Modified 
live virus vaccine OR MLV 
OR porcine reproductive 
respiratory syndrome virus 
modified live virus vaccine 
OR PRRSV MLV OR 
Attenuated PRRSV) 
1,898 
3 #1 AND #2 523 
Table1. Search Strategy using the ISU Web of Science interface from 2012-2018 111 
Study records: 112 
Data management 113 
End note reference management will be used to store Research Information System (RIS) files, 114 
and the 1st duplication will be conducted in this software. As it is not possible to extract RIS file 115 
from SIL, we will only import the relevant references into distiller list, noting separately how 116 
many were retrieved by the actual search. We will retain the number of items returned by the 117 
“Fostera” term and the number that were considered relevant.  An online systematic review 118 
software will be used to manage literature records and data. 119 
 Selection process 120 
At least two reviewers will independently read all abstracts/summaries identified from the 121 
search. Full reports will be acquired if one reviewer identifies the abstract as potentially relevant. 122 
The full manuscripts will be further assessed by at least two reviewers and if again deemed 123 
relevant, all data will be extracted.  124 
The 1st level (abstract/title) screening question: 125 
1. Does the title or abstract indicate primary research describing a challenge trial for the Fostera 126 
MLV PRRSV or treatment in growing pigs? 127 
The 2nd level (full text) screening questions: 128 
1. Is the full text available in English? 129 
2. Does the study have at least 2 arms and one is Fostera administered per the label and another 130 
is challenged and unvaccinated? 131 
3. Does the study contain at least one of the three outcomes or interest: macroscopic lesion mean 132 
score, level of viremia, duration of viremia and/or average daily gain (ADG)? 133 
Data collection process:  134 
Study level information 135 
1. What is the study id? 136 
2. What was the year of the publication? 137 
3. What was the year of study conduct? 138 
4. What was the country of trial?  139 
 5. Describe the Age and weight units at enrollment? 140 
6. What was the gender composition? 141 
7. What was breed or genetic line? 142 
8. Number of groups in the design? 143 
9. Pigs were challenged before or after vaccination? 144 
10. Time from acquisition to vaccination(days)? 145 
11. Number of days between vaccination and challenge? 146 
12. Frequency of vaccination? 147 
13. Vaccination route(s)? 148 
14. Challenge route(s)? 149 
15. Dose of challenge? 150 
16. Which PRRSv strain was used as inoculum? 151 
17. Report percentage genetic similarity of challenged strain with Fostera vaccine strain? 152 
18. Days between PRRSv challenge and necropsy? 153 
19. What outcome was reported? 154 
20. What is the next outcome you want to report? 155 
Arm level information 156 
1. Number of treatment groups? 157 
2. What method was used for randomization? 158 
3. How many pigs were allocated in Fostera vaccinated and challenged group? 159 
4. How many pigs were allocated in unvaccinated and challenged i.e. control group? 160 
5. How many pigs were allocated in another group? 161 
6. How many weeks of age, they were vaccinated? 162 
 7. What was the mean macroscopic lung lesion score in Fostera vaccinated and challenged 163 
group? 164 
8.  What was the mean macroscopic lung lesion score in unvaccinated and challenged 165 
group? 166 
9. What was the level of viremia in Fostera vaccinated and challenged group? 167 
10. What was the level of viremia in unvaccinated and challenged group? 168 
11. What was the duration of viremia in Fostera vaccinated and challenged group? 169 
12. What was the duration of viremia in unvaccinated and challenged group? 170 
13. What was the mean average daily weight gain in Fostera vaccinated and challenged 171 
group? 172 
14. What was the mean average daily weight gain in unvaccinated and challenged group? 173 
Data collection process 174 
Data extraction will be completed independently by at least two reviewers from all eligible 175 
manuscripts. In the event, same study is obtained from multiple sources (i.e. conference 176 
proceedings and a manuscript from MEDLINE), the different sources will be combined to obtain 177 
the most complete trail description. 178 
Data items 179 
Source of heterogeneity  180 
The source of heterogeneity will be PRRSV challenged strain as inoculum, age of pigs when 181 
they are purchased, source from where they are purchased, breed of pigs, weight of pig before 182 
the start of trial, number of days for acclimation before the start of trial, number of pigs per 183 
 group, number of groups, challenge dose, route of challenge, individually housed or group 184 
housed. 185 
Study level information 186 
Country where study was conducted, year of conduct, pig mean age, mean weight, gender 187 
composition, breed or genetic line of pigs involved, duration of study observation period. 188 
Arm level information 189 
Interventions used in each arm (PRRSV strain, dose, route, duration) total number of pigs in trial 190 
arm, number of events (high lung lesion score) in trial arm at the end of study period, mean  lung 191 
lesion score outcome per trial arm, mean score of lung lesion score outcome per trial arm, 192 
pharmaceutical sponsorship of treatment, description of blinding of outcome assessment 193 
included (yes/no), description of use of randomization to group (yes/no), use of systematic 194 
allocation to treatment arm (yes/no), and use of allocation restrictions (blocking by time, 195 
blocking by weight, stratification by severity, stratification by sex). 196 
Outcomes and prioritization 197 
The primary outcome of interest is mean score of macroscopic lung lesions, and secondary 198 
outcomes of interest are level of viremia, duration of viremia and average daily gain (ADG). 199 
Risk of bias in individual studies 200 
The Cochrane Risk of Bias Scale for intervention studies will be used to assess bias for all 201 
outcomes together (macroscopic, magnitude and duration of viremia, and ADG) as these are all 202 
considered objective outcomes (Higgins et al., 2011). The bias domains include selection bias 203 
(sequence generation and allocation concealment), detection bias (outcome assessor blinding), 204 
 attrition bias (incomplete outcome data), reporting bias (selective outcome reporting), and other 205 
potential sources of bias. Two reviewers will be independently assessing all sources of bias as 206 
“high risk”, “low risk”, or “unclear”. This information will be used as a source of heterogeneity 207 
in the meta-analysis. 208 
Data Synthesis 209 
We propose to conduct a meta-analysis using a pair-wise comparison. The suitability of the 210 
dataset for this method will be determined when data has been extracted in consultation with a 211 
statistician. Unit of analysis will be handled by exclusion as all studies must have the individual 212 
as the unit of allocation. Studies with missing data will be excluded from the meta-analysis and 213 
identified as such in the results.  214 
Subgroup analysis will include assessment of factors associated with methodological and clinical 215 
heterogeneity. The methodological factors (sponsorship and blinding) will be used to assess the 216 
systematic bias between studies where the null hypothesis is the beta estimates of the trial factors 217 
equal zero. We expect the potential sources of clinical heterogeneity to be the PRRSV strain, 218 
number of pigs per group, number of groups, challenge dose, route of challenge, calculation of 219 
outcomes, lung lesion evaluation DPC. We will assess this including these factors as indicator 220 
variables in the model where the null hypothesis is the beta estimates of the trial factors equal 221 
zero. 222 
If quantitative synthesis is determined to be unfeasible, a systematic narrative synthesis paired 223 
with descriptive pairwise forest plots will be produced explaining the characteristics and findings 224 
within and between included studies. 225 
Meta-bias(es) 226 
 To assess publication bias, we will attempt use a selection model based on study size, study 227 
design, estimated effect size, and sponsorship to determine estimates of propensity for 228 
publication (Mavridis et al., 2014). Based on previous reviews, it is unclear how many different 229 
study designs (e.g. active-to-active, placebo-controlled trials, three arm trials) will be observed 230 
and thus publication bias will be difficult to ascertain.  231 
Confidence in cumulative evidence 232 
 We will summarize the data using the GRADE approach, with a summary of findings tables and 233 
evidence profiles for the multiple outcomes. All the outcomes are considered important or 234 
critical.  235 
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1. Is the full text available in English? 129 
2. Does the study have at least 2 arms and one is Fostera administered per the label and another 130 
is challenged and unvaccinated? 131 
3. Does the study contain at least one of the three outcomes or interest: macroscopic lesion mean 132 
score, level of viremia, duration of viremia and/or average daily gain (ADG)? 133 
Data collection process:  134 
Study level information 135 
1. What is the study id? 136 
2. What was the year of the publication? 137 
3. What was the year of study conduct? 138 
4. What was the country of trial?  139 
 5. Describe the Age and weight units at enrollment? 140 
6. What was the gender composition? 141 
7. What was breed or genetic line? 142 
8. Number of groups in the design? 143 
9. Pigs were challenged before or after vaccination? 144 
10. Time from acquisition to vaccination(days)? 145 
11. Number of days between vaccination and challenge? 146 
12. Frequency of vaccination? 147 
13. Vaccination route(s)? 148 
14. Challenge route(s)? 149 
15. Dose of challenge? 150 
16. Which PRRSv strain was used as inoculum? 151 
17. Report percentage genetic similarity of challenged strain with Fostera vaccine strain? 152 
18. Days between PRRSv challenge and necropsy? 153 
19. What outcome was reported? 154 
20. What is the next outcome you want to report? 155 
Arm level information 156 
1. Number of treatment groups? 157 
2. What method was used for randomization? 158 
3. How many pigs were allocated in Fostera vaccinated and challenged group? 159 
4. How many pigs were allocated in unvaccinated and challenged i.e. control group? 160 
5. How many pigs were allocated in another group? 161 
6. How many weeks of age, they were vaccinated? 162 
 7. What was the mean macroscopic lung lesion score in Fostera vaccinated and challenged 163 
group? 164 
8.  What was the mean macroscopic lung lesion score in unvaccinated and challenged 165 
group? 166 
9. What was the level of viremia in Fostera vaccinated and challenged group? 167 
10. What was the level of viremia in unvaccinated and challenged group? 168 
11. What was the duration of viremia in Fostera vaccinated and challenged group? 169 
12. What was the duration of viremia in unvaccinated and challenged group? 170 
13. What was the mean average daily weight gain in Fostera vaccinated and challenged 171 
group? 172 
14. What was the mean average daily weight gain in unvaccinated and challenged group? 173 
Data collection process 174 
Data extraction will be completed independently by at least two reviewers from all eligible 175 
manuscripts. In the event, same study is obtained from multiple sources (i.e. conference 176 
proceedings and a manuscript from MEDLINE), the different sources will be combined to obtain 177 
the most complete trail description. 178 
Data items 179 
Source of heterogeneity  180 
The source of heterogeneity will be PRRSV challenged strain as inoculum, age of pigs when 181 
they are purchased, source from where they are purchased, breed of pigs, weight of pig before 182 
the start of trial, number of days for acclimation before the start of trial, number of pigs per 183 
 group, number of groups, challenge dose, route of challenge, individually housed or group 184 
housed. 185 
Study level information 186 
Country where study was conducted, year of conduct, pig mean age, mean weight, gender 187 
composition, breed or genetic line of pigs involved, duration of study observation period. 188 
Arm level information 189 
Interventions used in each arm (PRRSV strain, dose, route, duration) total number of pigs in trial 190 
arm, number of events (high lung lesion score) in trial arm at the end of study period, mean  lung 191 
lesion score outcome per trial arm, mean score of lung lesion score outcome per trial arm, 192 
pharmaceutical sponsorship of treatment, description of blinding of outcome assessment 193 
included (yes/no), description of use of randomization to group (yes/no), use of systematic 194 
allocation to treatment arm (yes/no), and use of allocation restrictions (blocking by time, 195 
blocking by weight, stratification by severity, stratification by sex). 196 
Outcomes and prioritization 197 
The primary outcome of interest is mean score of macroscopic lung lesions, and secondary 198 
outcomes of interest are level of viremia, duration of viremia and average daily gain (ADG). 199 
Risk of bias in individual studies 200 
The Cochrane Risk of Bias Scale for intervention studies will be used to assess bias for all 201 
outcomes together (macroscopic, magnitude and duration of viremia, and ADG) as these are all 202 
considered objective outcomes (Higgins et al., 2011). The bias domains include selection bias 203 
(sequence generation and allocation concealment), detection bias (outcome assessor blinding), 204 
 attrition bias (incomplete outcome data), reporting bias (selective outcome reporting), and other 205 
potential sources of bias. Two reviewers will be independently assessing all sources of bias as 206 
“high risk”, “low risk”, or “unclear”. This information will be used as a source of heterogeneity 207 
in the meta-analysis. 208 
Data Synthesis 209 
We propose to conduct a meta-analysis using a pair-wise comparison. The suitability of the 210 
dataset for this method will be determined when data has been extracted in consultation with a 211 
statistician. Unit of analysis will be handled by exclusion as all studies must have the individual 212 
as the unit of allocation. Studies with missing data will be excluded from the meta-analysis and 213 
identified as such in the results.  214 
Subgroup analysis will include assessment of factors associated with methodological and clinical 215 
heterogeneity. The methodological factors (sponsorship and blinding) will be used to assess the 216 
systematic bias between studies where the null hypothesis is the beta estimates of the trial factors 217 
equal zero. We expect the potential sources of clinical heterogeneity to be the PRRSV strain, 218 
number of pigs per group, number of groups, challenge dose, route of challenge, calculation of 219 
outcomes, lung lesion evaluation DPC. We will assess this including these factors as indicator 220 
variables in the model where the null hypothesis is the beta estimates of the trial factors equal 221 
zero. 222 
If quantitative synthesis is determined to be unfeasible, a systematic narrative synthesis paired 223 
with descriptive pairwise forest plots will be produced explaining the characteristics and findings 224 
within and between included studies. 225 
Meta-bias(es) 226 
 To assess publication bias, we will attempt use a selection model based on study size, study 227 
design, estimated effect size, and sponsorship to determine estimates of propensity for 228 
publication (Mavridis et al., 2014). Based on previous reviews, it is unclear how many different 229 
study designs (e.g. active-to-active, placebo-controlled trials, three arm trials) will be observed 230 
and thus publication bias will be difficult to ascertain.  231 
Confidence in cumulative evidence 232 
 We will summarize the data using the GRADE approach, with a summary of findings tables and 233 
evidence profiles for the multiple outcomes. All the outcomes are considered important or 234 
critical.  235 
